Macrogenics Inc

+0.57 (+9.63%)
: $6.60 +0.11 (+1.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)437.40M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$81.69 Million
Adjusted EPS$0.25
See more estimates
10-Day MA$6.32
50-Day MA$4.76
200-Day MA$5.42
See more pivots

Macrogenics Inc Stock, NASDAQ:MGNX

9704 Medical Center Drive, Rockville, Maryland 20850-3368
United States of America
Phone: +1.301.251.5172
Number of Employees: 427


MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.